Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Ceapro Inc V.CZO

Ceapro Inc. is a Canada-based biotechnology company. The Company is involved in the development of extraction technology and the application of this technology to the production of extracts and active ingredients from oats and other renewable plant resources. Its primary business activities relate to the development and commercialization of natural products for personal care, cosmetic, human, and animal health industries using technology, natural, renewable resources, and developing products, technologies, and delivery systems. The Company's products include a commercial line of natural active ingredients, including beta glucan, avenanthramides (colloidal oat extract), oat powder, oat oil, oat peptides, and lupin peptides, a commercial line of natural anti-aging skincare products, utilizing active ingredients, including beta glucan and avenanthramides and veterinary therapeutic products, including an oat shampoo, an ear cleanser, and a dermal complex/conditioner.


TSXV:CZO - Post by User

Comment by Ciaoon Jan 27, 2022 9:24pm
87 Views
Post# 34369500

RE:RE:60% gross margin is the target

RE:RE:60% gross margin is the targetQ3 was a great quarter for them wrt operating expenses, maybe that can be repeated over the next 4 quarters, maybe not.

Why not just look at the quarterly financials and add up the net income and R&D for each quarter and it comes up to about $5M for first 9 months. I don't think net income and R&D will be $4.1M in Q4, but still better than Q3, maybe $2.5M for Q3 for a total of $7.5M in 2021.


prophetoffacts wrote: Not this simple but just to provoke...

Q3 profit $875,000 X 4 = $3.5 million annually.

Q3 R&D spend $1.4 million X 4 = $5.6 million annually.

Q3 Annualized Profit + Q3 Annualized R&D spend = $9.1 million.

Market cap = $30 net of cash.

Yield 30.1% on net of cash basis.


prophetoffacts wrote: This is BIG. Let it sink in!

Indications are for "solid" double digit growth for the base business for 2021. Assuming by "solid" it is meant about 11% growth over 2020 that would mean approximately $16.63 million in revenue for 2021.

The stunningly improved 60% gross margin in the last two quarters in the new consolidated facility is not an anomaly. It is believed sustainable and represents the long-term target for the company.

Everyone should run a 60% gross margin through a full year with another year of 10% growth and see what you get for 2022! Essentially you get average revenue per quarter about equal to Q3 2021. Look at the $875,000 net profit in that quarter and add back the $1.4 million R&D spend! What is the forward yield given the $30 market cap net of cash currently?



 




<< Previous
Bullboard Posts
Next >>